Bendamustine

Generic Name: Bendamustine

Brand Names: Belrapzo, Bendeka, Treanda, Vivimusta

Drug Type: Small Molecule

Chemical Formula: C_₁₆H_₂₁Cl_₂N_₃O_₂

CAS Number: 16506-27-7

Unique Ingredient Identifier: 9266D9P3PQ

Background: Bendamustine is a nitrogen mustard drug indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Bendamustine is a bifunctional mechlorethamine derivative capable of forming electrophilic alkyl groups that covalently bond to other molecules. Through this function as an alkylating agent, bendamustine causes intra- and inter-strand crosslinks between DNA bases resulting in cell death. It is active against both active and quiescent cells, although the exact mechanism of action is unknown.

Indication: Bendamustine is indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.

Associated Conditions: Chronic Lymphocytic Leukemia, Follicular Non-Hodgkin's Lymphoma Refractory, Refractory Hodgkin Lymphoma, Refractory Mantle Cell Lymphoma, Waldenström's Macroglobulinemia (WM), Recurrent multiple myeloma, Refractory indolent B cell non-hodgkin lymphoma

Clinical Trials

FT522 With Rituximab in Relapsed/Refractory B-Cell Lymphoma (FT522-101)

Phase 1

Recruiting

Conditions: Relapsed/Refractory B-Cell Lymphoma

Interventions: Drug: FT522
Drug: Rituximab
Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Bendamustine

First Posted Date: 2023-07-18

Last Posted Date: 2024-07-26

Lead Sponsor: Fate Therapeutics

Target Recruit Count: 166

Registration Number: NCT05950334

Locations: 🇺🇸
Karmanos Cancer Center, Detroit, Michigan, United States
🇺🇸
University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, United States
🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States

and more 3 locations

FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma

Phase 1

Withdrawn

Conditions: Diffuse Large B Cell Lymphoma
Transformed Indolent Non-Hodgkin's Lymphoma
Follicular Lymphoma
Mantle Cell Lymphoma
Marginal Zone Lymphoma

Interventions: Drug: FT596
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Vincristine
Drug: Prednisone
Drug: Rituximab
Drug: Bendamustine

First Posted Date: 2023-07-06

Last Posted Date: 2023-07-06

Lead Sponsor: Fate Therapeutics

Registration Number: NCT05934097

Zanubrutinib Plus BR in Newly Diagnosed Symptomatic WM

Phase 2

Recruiting

Conditions: Waldenstrom Macroglobulinemia

Interventions: Drug: Zanubrutinib, Bendamustine and Rituximab

First Posted Date: 2023-06-22

Last Posted Date: 2024-08-28

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 42

Registration Number: NCT05914662

Locations: 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China

A Real-world Study of Obinutuzumab-based Therapy for Previously Untreated FL

Recruiting

Conditions: Follicular Lymphoma

Interventions: Drug: Obinutuzumab
Drug: Cyclophosphamide
Drug: Lenalidomide
Drug: Bendamustine
Drug: Doxorubicin
Drug: Vincristine
Drug: Prednisone

First Posted Date: 2023-06-12

Last Posted Date: 2023-06-12

Lead Sponsor: Ruijin Hospital

Target Recruit Count: 332

Registration Number: NCT05899621

Locations: 🇨🇳
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China

Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy

Phase 2

Recruiting

Conditions: Relapsed Follicular Lymphoma
Refractory Follicular Lymphoma

Interventions: Drug: Epcoritamab
Drug: Investigation agent 2
Drug: Investigation agent 3
Drug: Lenalidomide
Drug: Rituximab
Drug: Obinutuzumab
Drug: Bendamustine
Drug: Vincristine
Drug: Doxorubicin
Drug: Cyclophosphamide
Drug: Prednisone

First Posted Date: 2023-05-08

Last Posted Date: 2023-11-29

Lead Sponsor: University of Birmingham

Target Recruit Count: 284

Registration Number: NCT05848765

Locations: 🇬🇧
Cardiff and vale University LHB, Cardiff, United Kingdom
🇬🇧
Belfast Health & Social Care Trust, Belfast, United Kingdom
🇬🇧
NHS Grampian, Aberdeen, United Kingdom

and more 22 locations

A Trial Comparing Chemotherapy Versus Novel Immune Checkpoint Inhibitor (Pembrolizumab) Plus Chemotherapy in Treating Relapsed/Refractory Classical Hodgkin Lymphoma

Phase 3

Withdrawn

Conditions: Recurrent Classic Hodgkin Lymphoma
Refractory Classic Hodgkin Lymphoma

Interventions: Procedure: Autologous Hematopoietic Stem Cell Transplantation
Drug: Bendamustine
Drug: Brentuximab Vedotin
Drug: Carboplatin
Procedure: Computed Tomography
Drug: Etoposide
Drug: Gemcitabine
Drug: Ifosfamide
Drug: Pegylated Liposomal Doxorubicin Hydrochloride
Procedure: Positron Emission Tomography
Biological: Pembrolizumab
Radiation: Radiation Therapy
Other: Transplant Conditioning
Drug: Vinorelbine

First Posted Date: 2023-02-03

Last Posted Date: 2024-03-20

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT05711628

A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)

Phase 3

Active, not recruiting

Conditions: Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma

Interventions: Drug: Nemtabrutinib
Drug: Fludarabine
Drug: Cyclophosphamide
Drug: Bendamustine
Biological: Rituximab
Biological: Truxima
Biological: Ruxience
Biological: Riabni

First Posted Date: 2022-11-22

Last Posted Date: 2024-12-24

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 300

Registration Number: NCT05624554

Locations: 🇺🇸
Highlands Oncology Group ( Site 5205), Springdale, Arkansas, United States
🇺🇸
Clermont Oncology Center ( Site 5224), Clermont, Florida, United States
🇺🇸
Hattiesburg Clinic Hematology/Oncology ( Site 5216), Hattiesburg, Mississippi, United States

and more 94 locations

A Study of Tazemetostat With Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma

Phase 1

Recruiting

Conditions: Follicular Lymphoma

Interventions: Drug: Bendamustine
Drug: Rituximab
Drug: Tazemetostat

First Posted Date: 2022-09-23

Last Posted Date: 2025-05-04

Lead Sponsor: Vaishalee Kenkre

Target Recruit Count: 42

Registration Number: NCT05551936

Locations: 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸
University of Illinois Cancer Center, Chicago, Illinois, United States
🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

and more 2 locations

A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008)

Phase 2

Active, not recruiting

Conditions: Hodgkin Lymphoma

Interventions: Biological: favezelimab/pembrolizumab
Drug: bendamustine
Drug: gemcitabine

First Posted Date: 2022-08-19

Last Posted Date: 2025-04-03

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 200

Registration Number: NCT05508867

Locations: 🇨🇳
Sun Yat-sen University Cancer Center ( Site 0500), Guangzhou, Guangdong, China
🇺🇸
The University of Arizona Cancer Center - North Campus ( Site 2216), Tucson, Arizona, United States
🇺🇸
UCLA Hematology/Oncology - Santa Monica ( Site 2208), Los Angeles, California, United States

and more 102 locations

Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis

Phase 1

Recruiting

Conditions: AL Amyloidosis

Interventions: Drug: Venetoclax Oral Tablet, 200 mg
Drug: Venetoclax MTD with Dexamethasone
Drug: Venetoclax Oral Tablet, 400 mg
Device: FISH assay
Drug: Daratumumab Injection
Drug: Dexamethasone Oral, 10 mg
Drug: Dexamethasone Oral, 20 mg
Drug: Bendamustine
Drug: Pomalidomide
Drug: Ixazomib

First Posted Date: 2022-07-11

Last Posted Date: 2024-06-28

Lead Sponsor: Rajshekhar Chakraborty, MD

Target Recruit Count: 53

Registration Number: NCT05451771

Locations: 🇺🇸
New York Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York, United States
🇺🇸
Mayo Clinic Rochester, Rochester, Minnesota, United States
🇺🇸
Froedtert Hospital & the Medical College of Wisconsin, Milwaukee, Wisconsin, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy